Xponance Inc. Reduces Stock Holdings in Catalent, Inc. (NYSE:CTLT)

Xponance Inc. lowered its position in Catalent, Inc. (NYSE:CTLT) by 11.7% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 23,265 shares of the company’s stock after selling 3,083 shares during the quarter. Xponance Inc.’s holdings in Catalent were worth $1,045,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently modified their holdings of the company. Gladius Capital Management LP purchased a new position in Catalent during the third quarter worth about $28,000. Exchange Traded Concepts LLC purchased a new position in Catalent during the third quarter worth about $31,000. Cary Street Partners Investment Advisory LLC boosted its stake in Catalent by 1,162.3% during the third quarter. Cary Street Partners Investment Advisory LLC now owns 770 shares of the company’s stock worth $35,000 after buying an additional 709 shares during the period. Rakuten Securities Inc. purchased a new position in Catalent during the fourth quarter worth about $46,000. Finally, Federated Hermes Inc. purchased a new position in Catalent during the fourth quarter worth about $46,000.

Catalent Stock Down 0.2 %

Shares of NYSE:CTLT opened at $55.92 on Thursday. The firm’s 50 day moving average price is $56.78 and its 200 day moving average price is $48.48. The stock has a market cap of $10.12 billion, a price-to-earnings ratio of -8.22, a price-to-earnings-growth ratio of 6.05 and a beta of 1.20. Catalent, Inc. has a fifty-two week low of $31.45 and a fifty-two week high of $60.20. The company has a quick ratio of 1.73, a current ratio of 2.48 and a debt-to-equity ratio of 1.34.

Catalent (NYSE:CTLT) last issued its earnings results on Friday, February 9th. The company reported ($0.24) earnings per share for the quarter, missing the consensus estimate of ($0.02) by ($0.22). Catalent had a negative net margin of 29.91% and a negative return on equity of 2.43%. The firm had revenue of $1.03 billion during the quarter, compared to analyst estimates of $1.01 billion. During the same period last year, the business earned $0.62 EPS. The firm’s revenue was down 10.2% compared to the same quarter last year. As a group, equities research analysts predict that Catalent, Inc. will post 0.28 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several brokerages have weighed in on CTLT. Barclays increased their target price on shares of Catalent from $45.00 to $47.00 and gave the stock an “equal weight” rating in a research note on Thursday, January 25th. StockNews.com assumed coverage on shares of Catalent in a research note on Friday, April 19th. They issued a “sell” rating for the company. Stephens reissued an “equal weight” rating and issued a $63.50 price objective on shares of Catalent in a research note on Thursday, April 4th. UBS Group reissued a “neutral” rating and issued a $63.50 price objective (up previously from $58.00) on shares of Catalent in a research note on Tuesday, February 6th. Finally, Royal Bank of Canada reissued a “sector perform” rating and issued a $63.50 price objective on shares of Catalent in a research note on Tuesday, February 20th. Two investment analysts have rated the stock with a sell rating, nine have issued a hold rating and three have given a buy rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Hold” and an average target price of $52.46.

Catalent Company Profile

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.